SHPHF (Sihuan Pharmaceutical Holdings Group) Moat Score: 3/10 (As of Jun. 30, 2026)


SHPHF Sihuan Pharmaceutical Holdings Group Ltd SHPHF
51 GF Score
Price $0.13
GF Value $0.18
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sihuan Pharmaceutical Holdings Group Moat Score?

Sihuan Pharmaceutical Holdings Group SHPHF 51 Moat Score is 3 as of Jun. 30, 2026. GuruFocus rates SHPHF with a GF Score™ of 51/100 and a GF Value™ of $0.18 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Sihuan Pharmaceutical Holdings Group ranks better than 86.12% on this metric.

Sihuan Pharmaceutical Holdings Group has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Sihuan Pharmaceutical Holdings Group has No Moat: Sihuan Pharmaceutical has limited market share and lacks strong brand strength or customer loyalty. The company does not possess significant intellectual property or regulatory barriers, leading to a transient competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Sihuan Pharmaceutical Holdings Group might have No Moat - Very weak/transient advantages.

Sihuan Pharmaceutical Holdings Group  (OTCPK:SHPHF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Sihuan Pharmaceutical Holdings Group Moat Score Related Terms

SHPHF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sihuan Pharmaceutical Holdings Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sihuan Pharmaceutical Holdings Group Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sihuan Pharmaceutical Holdings Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Sihuan Pharmaceutical Holdings Group's Moat Score falls into.


SHPHF
51GF Score
Sihuan Pharmaceutical Holdings Group Ltd SHPHF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Sihuan Pharmaceutical Holdings Group (SHPHF) has a Moat Score of 3 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #143 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 13.9%.
Is Sihuan Pharmaceutical Holdings Group's Moat Score too high?
Sihuan Pharmaceutical Holdings Group's current Moat Score is 3. Based on the distribution chart, Sihuan Pharmaceutical Holdings Group ranks #143 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sihuan Pharmaceutical Holdings Group has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sihuan Pharmaceutical Holdings Group's Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sihuan Pharmaceutical Holdings Group ranks #143 out of 1030 companies for Moat Score. This places Sihuan Pharmaceutical Holdings Group in the top 14% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Sihuan Pharmaceutical Holdings Group's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sihuan Pharmaceutical Holdings Group stock overvalued right now?
Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group (SHPHF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.18, compared to a current price of $0.13 — trading 27.9% below its estimated fair value. The current Moat Score is 3. Sihuan Pharmaceutical Holdings Group's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Sihuan Pharmaceutical Holdings Group (SHPHF), the current Moat Score is 3 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sihuan Pharmaceutical Holdings Group (SHPHF) Overvalued in 2026?

Based on GuruFocus' analysis, Sihuan Pharmaceutical Holdings Group stock appears to be undervalued. The current stock price of $0.13 is trading 27.9% below its estimated GF Value™ of $0.18. GuruFocus considers Sihuan Pharmaceutical Holdings Group to be Modestly Undervalued.

Key valuation signals for SHPHF:

  • Moat Score: 3
  • GF Value™: $0.18 vs. price of $0.13 (27.9% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the SHPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sihuan Pharmaceutical Holdings Group Business Description

Other Exchanges 00460:Hong KongTEL1:Germany
Address 1 Harbour Road, Convention Plaza, Room 4905, Office Tower, Wanchai, HKG
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
51GF Score

Get the complete analysis for SHPHF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.18
GF Value